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Phospholipase associated neurodegeneration (PLAN) comprises a heterogeneous group of autosomal
recessive neurological disorders caused by mutations in the PLA2G6 gene. Direct gene sequencing detects
85% mutations in infantile neuroaxonal dystrophy. We report the novel use of multiplex ligation-
dependent probe ampliﬁcation (MLPA) analysis to detect novel PLA2G6 duplications and deletions. The
identiﬁcation of such copy number variants (CNVs) expands the PLAN mutation spectrum and may
account for up to 12.5% of PLA2G6 mutations. MLPA should thus be employed to detect CNVs of PLA2G6
in patients who show clinical features of PLAN but in whom both disease-causing mutations cannot be
identiﬁed on routine sequencing.
 2010 Elsevier Inc. All rights reserved.Introduction
Autosomal recessive neurodegeneration associated with genetic
defects in the PLA2G6 gene [1] may present with a number of phe-
notypes [2] including presentation in infancy [3,4] (infantile neuro-
axonal dystrophy, INAD, MIM256600), childhood (atypical
neuroaxonal dystrophy, neurodegeneration with brain iron accu-
mulation, NBIA MIM610217, Karak syndrome MIM608395) [4,5]
and also in adulthood [6,7] (early-onset dystonia-parkinsonism
MIM612953). Mutation detection rate is particularly high (80–ll rights reserved.
Court, Birmingham Women’s
B15 2TG, UK.
an@bham.ac.uk (M.A. Kurian).90%) in children with classical clinical and radiological features
of infantile PLAN [2,8].1
Classical INAD (infantile onset PLAN) accounts for the majority
of cases, and is characterised by infantile onset truncal hypotonia
and progressive psychomotor regression [3,4]. Over time, children
develop bulbar dysfunction, pyramidal tract signs, optic atrophy,
cerebellar features and extrapyramidal features [3,4,9–12]. MRI
features can aid diagnosis [13–15]. The majority of patients have
features of cerebellar atrophy [4]. Cerebellar gliosis is seen in the
majority [4] but not all patients have this feature [16]. Some also
have evidence of brain iron accumulation [3,4]. Generalised sei-
zures are often reported [17–19]. Dysmorphia is rarely described
[20]. Death usually occurs around the ﬁrst decade [3,4].1 Abbreviations used: PLAN, phospholipase associated neurodegeneration; MLPA,
multiplex ligation-dependent probe ampliﬁcation; ARMD, Alu recombination-med-
iated deletion.
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have mutations in the PLA2G6 gene [4]. Possible explanations for
this include genetic heterogeneity [1], PLA2G6 defects within intro-
nic sequence or regulatory regions and CNVs that are undetected
by standard diagnostic mutational screening strategies [21]. In re-
cent years, MLPA has emerged as a high resolution technique to
determine relative DNA sequence dosage [22,23].
We describe four children with infantile PLAN referred for diag-
nostic PLA2G6 screening in which both disease-causing mutations
were not identiﬁed on direct gene sequencing. Further investiga-
tion with MLPA analysis detected a novel heterozygous duplication
in patient 1 and a novel homozygous deletion in patients 2–4.Subjects and methods
Patients
The patients described were referred to the West Midlands Re-
gional Genetic Service for PLA2G6 analysis by their local paediatric
neurologist/geneticist. The medical case notes were analysed to
delineate the clinical features on history and examination. MRI
brain scans for patient 1 were reviewed independently by 2 paedi-
atric neuroradiologists (with consensus agreement on disparities).
Molecular genetic investigation
Techniques for DNA/RNA extraction, PLA2G6 sequencing, MLPA
analysis and molecular characterisation of the CNVs are outlined in
Supplementary data 1.Results
Clinical cases
Patient 1
Patient 1 was the ﬁrst child of non-consanguineous healthy
Caucasian parents. Early neurodevelopmental milestones were
achieved. At 15 months, he developed gait instability and an alter-
nating strabismus. Psychomotor regression ensued and by 19–
20 months of age, there was loss of ambulation. Between 2 and
3 years he developed 4-limb spasticity. Speech regression was also
evident. He developed severe bulbar dysfunction with excessive
drooling and feeding difﬁculties requiring PEG feeding. Dystonia
of all 4-limbs was also evident by age 5 years. He did not have
any seizures.
On clinical examination (age 5 years) he was not dysmorphic or
microcephalic, but had evidence of a right-sided manifest squint
and bilateral horizontal nystagmus. There was excessive drooling
and tongue fasciculation. On neurological assessment he was
found to have marked axial hypotonia. There was a postural kyph-
otic curvature of the spine. Limb examination revealed symmetri-
cal 4-limb hypertonicity and hyperreﬂexia but no contractures.
Plantar reﬂexes were upgoing bilaterally.
MRI brain examination was undertaken at age 2 and 2.9 years
(Fig. 1). Initial MRI scan showed evidence of a hypoplastic cere-
bellum and vermis (Fig. 1A and B). There was no evidence of op-
tic nerve hypoplasia or white matter abnormalities. On repeat
MR neuroimaging at age 2.9 years, there was progressive cere-
bellar atrophy (Fig. 1C and D). Although minimal basal ganglia
abnormalities were noted on initial imaging (Fig. 1E), mild iron
accumulation within the basal ganglia was evident on repeat
imaging (Fig. 1F). Electromyographic (EMG) signs of chronic
denervation were evident in the upper limbs, lower limbs and
bulbar musculature. Nerve conduction studies were normal. On
EEG, widespread high amplitude fast activity at 16–22 Hz wasseen. Visual evoked potentials (VEP) and electroretinogram
(ERG) was normal at age 2 years. Ophthalmological review de-
tected bilateral temporal disc pallor. Histological examination
of nerve tissue from a rectal biopsy (age 2 years) was normal.
Patient 2
Patient 2, a 4 year old girl was born to healthy consanguineous
(2nd cousin) Irish parents. All early developmental milestones
were appropriately achieved. Symptom onset at 9–10 months of
age commenced with psychomotor regression. She stopped vocal-
ising, developed complete loss of ambulation and could only sit for
brief periods with extensive support. There was no evidence of
seizures.
On clinical examination, at age 21 months, she was not dysmor-
phic or microcephalic. There was evidence of marked axial hypoto-
nia and upper and lower limb spasticity (but no contractures or
spinal deformity). She had evidence of nystagmus on clinical
examination. Ophthalmological examination did not detect any
abnormalities.
MRI brain (age 18 months) revealed cerebellar atrophy and a
marginally narrow pons but no evidence of basal ganglia abnormal-
ities. Electromyogram abnormalities were similar to patient 1. She
did not have any other electrophysiological investigations (VER,
ERG, EEG) or a sural/skin biopsy as repeatednon-attendance at clinic
appointments precluded further neurological investigation.
Patients 3 and 4
Patients 3 and 4, dizygotic male twins were born to healthy
consanguineous (1st cousin) parents, of Irish origin. There was no
family history of neurological disorders and the family were not
known to be related to patient 2’s kindred. The twins were born
at 33 weeks gestation, but despite their prematurity, the postnatal
course was uneventful. Early developmental milestones were
appropriately achieved, but concerns were raised at 11 months of
age as both children were yet to sit independently. At this stage
both children were noted to have strabismus. Psychomotor regres-
sion ensued in both children with a gradual but progressive loss of
cognitive and motor skills. A rapid decline in motor function was
seen in patient 3 subsequent to a febrile viral illness at age
22 months. Following this illness, he developed infantile spasms
associated with a hypsarrhythmic EEG pattern. At age 26 months,
patient 4 also developed seizures (generalised tonic clonic epi-
sodes) with an EEG pattern of high voltage slow background with
sharp and slow wave discharges seen independently in each tem-
poral region. Repeat EEG (5 months later) showed mild excess of
moderate voltage irregular slow activity with runs of high ampli-
tude irregular delta activity with ill deﬁned sharp components
independently over both temporal regions. Both children had oph-
thalmological assessments showing optic atrophy. Over time, both
children developed profound axial hypotonia, pyramidal tract fea-
tures and bulbar dysfunction.
MRI brain (at 24 months of age in both children) revealed mod-
erate cerebellar atrophy, but no cerebellar gliosis or brain iron
accumulation. Electrophysiological investigation revealed absent
sensory nerve action potentials associated with a myopathic pat-
tern on EMG. No clear binocular pattern of vision was evident on
VEP. A sural/skin biopsy was not undertaken in either patient.
Molecular genetic investigation
Direct sequencing of PLA2G6
Patient 1: A heterozygous mutation (c.1674delG; p.Leu560Trpf
sX5) was detected in exon 12 (Supplementary Fig. 1). A 2nd muta-
tion was not detected.
Patient 2–4: Molecular analysis did not detect any mutations in
exons 1–4 and 7–17 of the PLA2G6 gene. Repeated failed attempts
Fig. 1. MRI brain scan of patient 1. (A) and (B) Patient 1, age 2 years. (C) and (D) Patient 1, age 2.9 years. MR imaging. (E) Patient 1, age 2.0 years and (F) patient 1, age
2.9 years. (A) Coronal FLAIR sequence showing cerebellar atrophy, but no cerebellar grey matter gliosis. (B) Sagittal T2-weighted imaging showing marked atrophy of the
cerebellar vermis. (C) Coronal FLAIR sequence shows cerebellar atrophy which is slightly worse than shown on previous scan at age 2 years (1A). Still no gliosis/abnormal
signal is evident in the cerebellar grey matter. (D) Sagittal T2-weighted imaging showing marked atrophy of the cerebellar vermis. (E) Axial T2-weighted image showing very
subtle decrease in T2 signal (compared to normal age-matched controls) in the globus pallidi. (F) Axial T2-weighted image showing further reduction in T2 signal within the
globus pallidi.
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Supplementary Fig. 2) raised the possibility of an intragenic homo-
zygous deletion.MLPA analysis
Patient 1: A heterozygous duplication of exons 4, 5, 6 and 7 was
identiﬁed (Supplementary Fig. 3).
Patient 2–4: A homozygous deletion of exons 5 and 6 was de-
tected in all patients (Supplementary Fig. 4).Molecular genetic characterisation of the CNVs
Patient 1: Fig. 2A–D. Primers were designed for cDNA ampliﬁ-
cation of a putative tandem duplication from exon 7 to exon 4.
Subsequent sequencing of patient 1 conﬁrmed that the exon 4,
5, 6 and 7 duplication occurred within the PLA2G6 gene leading
to a pathogenic truncating mutation (r.426-?_1077-?dup
p.Lys360LeufsX22).
Patient 2–4: Fig. 2E–G. PCR primers were designed to amplify
the region between intron 4 and intron 6. The PCR ampliﬁcation
products were observed for patients but not in control samples.The genomic breakpoints were identiﬁed (g.40638_47282del6632,
p.Leu204_Glu298del95) in intron 4 (between 38 537 112 and 38
537 123 bp) and in intron 6 (between 38 530 480 and 38 530
491 bp). The breakpoints could not be further delineated as there
is a 12 bp region with 100% homology common to both intron 4
and intron 6.Discussion
To date, 75 different genetic alterations of PLA2G6 have been
reported in PLAN [1–4,6,8,12,17] including missense mutations
(68%), insertions (0.75%), deletions (14%), nonsense mutations
(14%) and splice site mutations (0.75%). We report the use of
MLPA in the detection of previously undetected novel large intra-
genic PLA2G6 rearrangements in four patients with classical infan-
tile PLAN. Although this only a recently reported diagnostic use of
MLPA in PLA2G6 analysis [21], this diagnostic tool has already been
successfully used in a number of other conditions [22,23] Indeed,
MLPA analysis of the SCN1A gene in mutation-negative patients
with Dravet’s syndrome detected a signiﬁcant chromosomal rear-
   I:1       I:2
Duplication Frameshift c.1674delG
:1
Duplication Frameshift c.1674delG
1      2      3       4        5      6      7
II:1  I:1   I:2   C1    C2   C3     N
A
B
C
D
Fig. 2. Molecular genetic investigation of patient 1–4. (A)–(D) RNA analysis for patient 1. (E)–(G) Determination of the genomic deletion breakpoint in patients 2–4. (A)
Forward and reverse primers designed to amplify a putative exon 7–4 junction fragment of 297 bp. Exon 7 sequence is highlighted in pink. Exon 4 sequence is highlighted in
blue. Designed primers are highlighted in yellow (7F, forward primer) and grey (4R, reverse primer). (B) Pedigree of family 1 illustrating both parental and patient 1’s disease
alleles. (C) Agarose gel photograph of results of PCR ampliﬁcation studies using primers 7F and 4R. Lane 1 – II:1 – Patient 1 – PCR product present. Lane 2 – I:1 – Father – PCR
product present. Lane 3 – I:2 – Mother – PCR product absent. Lane 4 – C1 – Control sample – PCR product absent. Lane 5 – C2 – Control sample – PCR product absent. Lane 6 –
C3 – Control sample – PCR product absent. Lane 7 – N – Negative control – PCR product absent. (D) Sequencing of PCR product in patient 1 (II:1) indicating that on RNA
analysis, exon 7 is spliced to exon 4. (E) DNA sequence of the region in which the breakpoint occurs. Alu Y sequence shown in green, region of 100% homology highlighted
grey. Intron 4 is in orange and intron 6 is in blue. Primers binding sites are underlined. (F) Agarose gel photograph of PCR ampliﬁcation of introns 4 and 6 of the PLA2G6 gene
showing the presence of bands in patient 2 and their parents and the absence of bands in the normal control. Lane 1 – Normal control – No PCR product. Lane 2 – Patient 2 –
PCR product of 450 bp. Lane 3 – Patient 2’s mother – PCR product of 450 bp. Lane 4 – Patient 2’s father – PCR product of 450 bp. Lane 5 – 1 Kb ladder. (G) Schematic
representation of the deletion breakpoint in patient 2. The exons that are present are indicated in red (exon 4 and 7). The deleted exons are represented in grey (exon 5 and 6).
The black triangles represent the AluY repeats in introns 4 and 6. There is a 12 base region of homologous sequence which show 100% homology in both intron 4 and 6
(shaded yellow box). (For interpretation of the references in colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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CNVs may also account for 12.5% PLA2G6 mutations identiﬁed in
the UK Diagnostic Screening Service.
MLPA analysis has important diagnostic implications. In patient
1, the heterozygous duplication could not be detected by standard
direct gene sequencing. In patient 2, failed attempts to amplify
exons 5 and 6 could have been due to a number of reasons (failed
PCR ampliﬁcation or the presence of rare SNP variants in primer
binding regions). However MLPA alone cannot provide an insight
as to the precise genomic location and/or potential functional out-
comes of the deletion/duplication [26]. Subsequent molecular
characterisation has provided important information regarding
the nature of these CNVs. In case 1, analysis of cDNA revealed
expression of mutant mRNA species containing a tandem duplica-
tion of exon 4, 5, 6, and 7, resulting in a frameshift and premature
stop codon. In case 2, genomic delineation of the centromeric and
telomeric breakpoints revealed that both breakpoints were within
an AluY repeat sequence (http://www.repeatmasker.org/) in intron
4 and intron 6 (showing 94% overall homology) (www.blast.nc-bi.nlm.nih.gov). An Alu recombination-mediated deletion (ARMD)
as a result of misalignment of the Alu Y repeats is thus the most
likely mechanism for generating this deletion. Deletion of exons
5 and 6 is predicted to lead to an inframe deletion which results
in partial loss of the seven ankyrin repeats of the PLA2G6 protein.
Ankyrin repeats mediate protein–protein interactions and loss or
disruption of this motif would be predicted to have a deleterious
effect on normal iPLA2-VI function.Conclusion
In conclusion, we describe the ﬁrst reported use of MLPA in
PLA2G6 analysis. Our data suggests that CNVs also have a role in
the pathogenesis of PLAN. As part of a PLA2G6 diagnostic screening
service, MLPA may contribute towards providing a deﬁnitive diag-
nosis in an affected individual. It may also help remove the need
for unnecessary neurological investigation, improve the quality of
genetic counselling and aid accurate prenatal diagnoses. It can
PCR product for intron 
4 to 6 amplification 
500bp 
  INTRON 4              INTRON 6 
      AluY                   AluY 
EXON 5 EXON 7 EXON 6 EXON 4 
INTRON 4 AluY Region of 100% homology INTRON 6 AluY 
E
F
G
Fig. 2 (continued)
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correlation as well as insights into sequence-related chromosomal
breakpoints, recombination hotspots and disease mechanisms. Our
observations thus have implications for molecular diagnosis and
highlight the importance of MLPA as a second-line diagnostic tool
and adjunct to direct sequencing in PLA2G6 screening.
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